Anti-Aging Peptides: Research Guide to Longevity Compounds

Aging research has shifted from describing age-related decline to understanding — and potentially intervening in — the molecular mechanisms that drive it. The nine hallmarks of aging identified by Lopez-Otin et al. (2013) provide a framework: genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, deregulated nutrient sensing, mitochondrial dysfunction, cellular senescence, stem cell exhaustion, and altered intercellular communication.

Peptides have emerged as research tools targeting several of these hallmarks simultaneously. Unlike small molecules that typically act on a single target, bioactive peptides often engage multiple signaling pathways — modulating gene expression, mitochondrial function, immune response, and extracellular matrix remodeling. This multi-target activity makes them particularly interesting for aging research, where the underlying biology is inherently multifactorial.

This guide surveys the peptides and compounds most actively studied in the context of aging and longevity, organized by their primary mechanism of action.

Nicotinamide adenine dinucleotide (NAD+) is a coenzyme present in every living cell, essential for mitochondrial energy production, DNA repair, sirtuin activation, and hundreds of enzymatic reactions. NAD+ levels decline with age — by approximately 50% between ages 40 and 60 — and this decline is implicated in multiple hallmarks of aging.

GHK-Cu is a naturally occurring tripeptide (glycyl-L-histidyl-L-lysine) with high affinity for copper(II) ions. It was first isolated from human plasma by Loren Pickart in 1973 and is found in saliva, urine, and colostrum. Plasma levels decline from approximately 200 ng/mL at age 20 to 80 ng/mL by age 60.

Epitalon (Ala-Glu-Asp-Gly) is a synthetic tetrapeptide based on the naturally occurring polypeptide epithalamin, extracted from the pineal gland. It was developed by Professor Vladimir Khavinson at the Saint Petersburg Institute of Bioregulation and Gerontology.

MOTS-c (Mitochondrial Open reading frame of the Twelve S rRNA type-c) is a 16-amino acid peptide encoded within the mitochondrial genome — specifically within the 12S rRNA gene. It was discovered by Changhan Lee and Pinchas Cohen at the University of Southern California in 2015.

MOTS-c is the first mitochondrial-derived peptide shown to have systemic metabolic effects. It activates AMPK (AMP-activated protein kinase), the master metabolic sensor, and has been demonstrated to regulate insulin sensitivity, fatty acid oxidation, and cellular stress responses.

Thymosin alpha-1 (Ta1) is a 28-amino acid peptide originally isolated from thymic tissue. It is the primary active component of thymosin fraction 5 and plays a central role in T-cell maturation and immune regulation.

In the context of aging research, thymosin alpha-1 is studied for its ability to counteract immunosenescence — the age-related decline in immune function that increases susceptibility to infections, cancers, and autoimmune disorders.

**Immune restoration:** Ta1 promotes the maturation of T-cell precursors, enhances dendritic cell function, and modulates the balance between Th1 and Th2 immune responses. In elderly subjects, Ta1 has been shown to improve vaccine responses — a practical measure of immune competence that typically declines with age.

**Anti-inflammatory effects:** Ta1 suppresses inflammasome activation and reduces the chronic low-grade inflammation ("inflammaging") that is characteristic of biological aging. It modulates toll-like receptor (TLR) signaling and reduces production of inflammatory cytokines including IL-1beta and IL-18.

**Clinical use:** Thymosin alpha-1 is one of the few anti-aging peptides with approved clinical applications in some countries (marketed for hepatitis B and C treatment and as an immune adjuvant). This provides a larger safety database than most research peptides in this category.

SS-31 (D-Arg-Dmt-Lys-Phe-NH2, also known as elamipretide or Bendavia) is a cell-permeable tetrapeptide that selectively concentrates in the inner mitochondrial membrane, where it binds to cardiolipin — a phospholipid essential for electron transport chain function.

**Mitochondrial mechanism:** Cardiolipin anchors the electron transport chain complexes in the inner mitochondrial membrane. With aging, cardiolipin undergoes oxidative damage and structural changes that impair electron transport efficiency, increase ROS production, and reduce ATP generation. SS-31 stabilizes cardiolipin structure, restoring electron transport efficiency and reducing mitochondrial ROS production.

**Preclinical aging data:** In aged mice, SS-31 treatment improved cardiac function, skeletal muscle performance, renal function, and neurovascular coupling. Notably, short-term treatment (8 weeks) in aged animals reversed decades of mitochondrial dysfunction in cardiac tissue, restoring ATP production and reducing oxidative stress to levels comparable to young controls.

**Clinical development:** SS-31 has been evaluated in clinical trials for Barth syndrome (a genetic cardiolipin disorder), heart failure, and age-related macular degeneration. The Barth syndrome trial demonstrated improved cardiac function and exercise capacity, validating the cardiolipin-stabilization mechanism in humans.

**Aging relevance:** SS-31 directly targets mitochondrial dysfunction — one of the nine hallmarks of aging — at its biophysical root. The ability to rapidly reverse age-related mitochondrial impairment with a short treatment course is particularly notable and has generated interest in periodic "mitochondrial rejuvenation" protocols.

When selecting peptides for aging research, the choice depends on which hallmark(s) of aging are under investigation:

**Telomere maintenance:** Epitalon (telomerase activation) **Mitochondrial dysfunction:** MOTS-c (AMPK activation, metabolic reprogramming), SS-31 (cardiolipin stabilization, electron transport chain) **NAD+ decline:** NAD+, NMN, NR (direct replenishment of the NAD+ pool for sirtuin activation and DNA repair) **Extracellular matrix / tissue remodeling:** GHK-Cu (collagen turnover, gene expression modulation, stem cell recruitment) **Immunosenescence:** Thymosin alpha-1 (T-cell maturation, inflammaging suppression) **Cellular senescence:** GHK-Cu (partial, via gene expression shifts), epitalon (via telomere extension)

Many aging researchers combine multiple compounds targeting different hallmarks, based on the rationale that aging is multifactorial and single-target interventions are unlikely to address all contributing mechanisms.